Related references
Note: Only part of the references are listed.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Kenji Ikeda et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives
M. Kudo
LIVER CANCER (2017)
Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
Richard Jackson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses
Toshiyuki Tamai et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Masafumi Ikeda et al.
CLINICAL CANCER RESEARCH (2016)
Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib
Takeshi Terashima et al.
HEPATOLOGY RESEARCH (2016)
Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study
Masatoshi Kudo et al.
LIVER INTERNATIONAL (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?
M. Kudo
LIVER CANCER (2015)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Yuji Yamamoto et al.
VASCULAR CELL (2014)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Why Does Every Hepatocellular Carcinoma Clinical Trial Using Molecular Targeted Agents Fail?
M. Kudo
LIVER CANCER (2012)
Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival
Goh Eun Chung et al.
RADIOLOGY (2011)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
